Acasti Pharma

143 articles with Acasti Pharma

• Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

  5/18/2022

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage (SAH), met all its planned study endpoints.

• Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th

  4/25/2022

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Prashant Kohli, Vice President of Commercial Operations of Acasti Pharma will be presenting at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022 at 4:30 pm ET.

• Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

  3/25/2022

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of Directors.

• Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan

  3/22/2022

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), announces the following patent notifications and awards relating to the Company’s three lead drug candidates.

• Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th

  3/9/2022

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma will be presenting at the 32nd Annual Oppenheimer Healthcare conference being held virtually March 15-17, 2022.

• Acasti Pharma Celebrates Rare Disease Day

  2/28/2022

  Acasti Pharma Inc. today recognizes and celebrates Rare Disease Day (February 28), as established by the European Organisation for Rare Diseases.

• Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022

  2/14/2022

  Acasti Pharma Inc. today provided a business update and announced its operating and financial results for the third quarter of its fiscal 2022 ended December 31, 2021.

• Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference CallCall to be held on Monday, February 14th at 1:00 PM Eastern Time

  2/7/2022

  Acasti Pharma Inc. today announced that it will host a conference call at 1:00 PM Eastern Time on Monday, February 14, 2022 to discuss the Company’s corporate progress and other developments, as well as financial results for the fiscal 2022 third quarter ended December 31, 2021.

• Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

  1/3/2022

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Acasti, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.

• Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1’22

  12/2/2021

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced positive results for GTX-104 based on its interim analysis of the first 20 of 50 normal healthy subjects in its pivotal pharmacokinetic (PK) bridging study.

• Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd

  11/24/2021

  Acasti Pharma Inc. today announced that Jan D’Alvise, President and CEO of Acasti Pharma, will be participating in the Benzinga All Access event taking place on December 2, 2021.

• Acasti Pharma Announces Annual Stock Option Grants - Nov 12, 2021

  11/12/2021

  Acasti Pharma Inc., announced the annual grant of stock options to its employees, executives and directors.

• Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022

  11/10/2021

  Acasti Pharma Inc., provided a business update and announced its operating and financial results for the second quarter of fiscal 2022 ended September 30, 2021.

• Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference CallCall to be held on Wednesday, November 10th at 1:00 PM Eastern Time

  11/4/2021

  Acasti Pharma Inc. today announced that it will host a conference call at 1:00 PM Eastern Time on Wednesday, November 10, 2021 to discuss the Company’s corporate progress and other developments, as well as financial results for the fiscal 2022 second quarter ended September 30, 2021.

• Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in JapanPatents strengthen Acasti’s IP portfolio and provide protection through 2036 and 2037, respectively

  10/6/2021

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office and the Mexican Patent Office have issued composition of matter patents for GTX-101, a novel bio-adhesive film forming topical spray formulation of bupivacaine for the treatment of Postherpetic Neuralgia (PHN).

• Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

  9/27/2021

  Acasti Pharma Inc. today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of intravenous (IV) GTX-104 compared to currently marketed oral nimodipine capsules in 50 healthy subjects.

• Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

  9/22/2021

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq’s minimum bid price requirement.

• Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

  9/14/2021

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.

• Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/8/2021

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced that Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021.

• Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

  8/27/2021

  Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger.